Clinical Trials Browser

Endometrial Neoplasms

NCT05256225 2026-04-22

Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma

Phase 3 Recruiting

360 enrolled

Gynecologic

Neoplasms, Endometrial Neoplasms

NCT03914612 2026-04-21

Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer

Phase 3 Active not recruiting

813 enrolled 16 charts 2 FDA

GynecologicSarcoma

Carcinosarcoma, Endometrial Neoplasms

NCT07198074 2026-04-21

Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer

Phase 3 Recruiting

255 enrolled

Gynecologic

Endometrial Neoplasms

NCT06952504 2026-04-17

TroFuse-033

Phase 3 Recruiting

1,123 enrolled

Gynecologic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Endometrial Neoplasms

NCT06746116 2026-04-16

DUoENDE

Phase 3 Active not recruiting

45 enrolled

Gynecologic

Endometrial Neoplasms

NCT03555422 2026-04-13

ENGOT-EN5

Phase 3 Completed

263 enrolled

Gynecologic

Genital Diseases, Neoplasms, Neoplasms by Site, Uterine Diseases, Uterine Neoplasms, Endometrial Neoplasms

NCT07044336 2026-04-13

Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)

Phase 3 Recruiting

700 enrolled

Gynecologic

Neoplasm Metastasis, Uterine Neoplasms, Endometrial Neoplasms

NCT06989112 2026-04-08

DE-01

Phase 3 Recruiting

600 enrolled

Gynecologic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Uterine Neoplasms, Endometrial Neoplasms

NCT06132958 2026-04-03

TroFuse-005

Phase 3 Active not recruiting

710 enrolled

Gynecologic

Endometrial Neoplasms

NCT06340568 2026-03-31

Fern-EC-01

Phase 3 Recruiting

480 enrolled

Gynecologic

Endometrial Neoplasms

NCT03517449 2026-03-19

MK-3475-775

Phase 3 Completed

827 enrolled 34 charts 2 FDA

Gynecologic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Endometrial Neoplasms

NCT04789694 2026-03-19

PHOCUS

Phase 3 Recruiting

64 enrolled

Gynecologic

Frailty, Ovarian Neoplasms, Endometrial Neoplasms

NCT07286331 2026-03-11

A Study to Investigate GSK5733584 Compared With Chemotherapy in Participants With Recurrent Endometrial Cancer (BEHOLD-Endometrial01)

Phase 3 Not yet recruiting

600 enrolled

Gynecologic

Endometrial Neoplasms

NCT07166094 2026-03-03

RAINFOL-03

Phase 3 Recruiting

544 enrolled

Gynecologic

Recurrence, Endometrial Neoplasms

NCT07022483 2026-02-04

Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer

Phase 3 Recruiting

710 enrolled

Gynecologic

Neoplasms, Endometrial Neoplasms

NCT03884101 2026-02-02

LEAP-001

Phase 3 Completed

842 enrolled 25 charts

Gynecologic

Endometrial Neoplasms

NCT05611931 2026-02-02

XPORT-EC-042

Phase 3 Recruiting

276 enrolled

Gynecologic

Endometrial Neoplasms

NCT04073706 2026-01-30

ENDO-3

Phase 3 Recruiting

760 enrolled

Gynecologic

Uterine Neoplasms, Endometrial Neoplasms

Clinical Trials

Vaginal Cuff Brachytherapy Fractionation Study

Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma

Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer

Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer

TroFuse-033

DUoENDE

ENGOT-EN5

Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)

DE-01

TroFuse-005

Fern-EC-01

MK-3475-775

PHOCUS

A Study to Investigate GSK5733584 Compared With Chemotherapy in Participants With Recurrent Endometrial Cancer (BEHOLD-Endometrial01)

RAINFOL-03

Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer

LEAP-001

XPORT-EC-042

ENDO-3